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Abstract
Background: Uveal Melanoma is a rare tumour that displays different clinical behavior and molecular features
compared with cutaneous melanoma. It is generally resistant to systemic therapy and there is no current standard
effective therapy to treat patients with advanced disease.
Patients and methods: We searched Medline, PubMed,
EMBASE and major oncology conference abstracts from the
past 5 years to identify relevant studies evaluating ipilimumab
monotherapy in uveal melanoma. Data were extracted on ipilimumab dose, sample size, Objective Response Rate (ORR),
Progression Free Survival (PFS), median Overall Survival
(mOS), Disease Control Rate (DCR), 1 year Overall Survival
(1yrOS) and 2 year Overall Survival (2yrOS).
Results: Nine studies were included in this study including
Phase II clinical trials (n = 2), Expanded Access Programs
(EAP) (n = 4) and retrospective studies (n = 3). Cases were
a mix of pre-treated and treatment-naïve patients. Reported mOS ranged from 5.2-28 months (median: 9.3 months),
and reported 1yrOS ranged between 4.5-65%. Calculated
compound ORR was 3.4%, and compound DCR was 36%.
Conclusion: Ipilimumab has limited clinical activity in advanced uveal melanoma. Further research is needed to
identify more effective systemic therapies for management
of these patients.
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Introduction
Uveal Melanoma (UM) is a rare tumour, with an estimated annual global incidence between 5.3-10.9 cases

per million people [1]. It accounts for less than 5% of all
melanoma cases [2]. UM arises from the vascular layers
of the eye (iris, ciliary body, and choroid). It is a highly
aggressive malignancy and about 50% of patients will
develop metastatic disease at some stage after prior
diagnosis of primary uveal melanoma [3]. Liver is the
dominant site of metastases (60-90%) followed by lungs
(25%) [4,5]. Prognosis in advanced disease is poor, with
median overall survival ranging between 2-15 months
[5-7].
UM has a distinct molecular profile, and displays
different clinical behavior to cutaneous melanoma. In
contrast to BRAF and NRAS mutations commonly seen
in cutaneous melanoma, mutations in heterotrimeric G
protein-α (GNA) subunits GNAQ and GNA11 have been
reported in up to 80% of uveal melanomas [8].
Treatment options for UM are particularly limited
and efficacy data is scarce [9]. There are a few small
studies that describe options such as chemotherapy,
metastasectomy, and hepatic intra-arterial chemoembolization [10]. Response rates are dismal [9], with one
retrospective review reporting response rates to systemic treatment being as low as 1% [3].
Immunotherapy has revolutionized the treatment
landscape for metastatic melanoma in the last 5 years.
Ipilimumab is a fully humanized monoclonal antibody
that blocks the Cytotoxic T-Lymphocyte-Associated Antigen 4 (CTLA-4), promoting anti-tumour immunity. It is
routinely used in metastatic melanoma, and was one
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of the first treatment to ever demonstrate a survival
benefit in large randomized trial in advanced melanoma
[11,12]. However, most of the studies examining activity of ipilimumab in advanced melanoma have traditionally excluded patients with uveal melanoma [11,12].
The aim of this paper was to conduct pool analysis
of published literature, evaluating the efficacy of ipilimumab monotherapy in the management of advanced
uveal melanoma.

Patients and Methods
This review was conducted in accordance with the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [13].

Identiﬁcation

MEDLINE, PubMed and EMBASE search was conducted to identify relevant articles, with no restrictions
placed on the search. All published prospective and retrospective studies, examining ipilimumimab activity in
advanced uveal melanoma, amongst both pre-treated
and treatment-naïve patients were included. Relevant
abstracts from the American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) annual scientific meetings presented in the
last 5 years were also evaluated. We used the following
search terms: “Uveal melanoma” and “ipilimumab”, in

Records identiﬁed through
database searching
(n = 42)

any combination in the titles of published trials or conference abstracts. Initial search results were screened
for duplication and relevance. The full articles and abstracts were then reviewed in detail. Data were manually extracted on study design, ipilimumab dose, sample
size, Objective Response Rate (ORR), Progression Free
Survival (PFS), Overall Survival (OS), Disease Control
Rate (DCR), 1 year Overall Survival (1yrOS) and 2 year
Overall Survival (2yrOS). Note was made of any limitations and bias present in individual studies.
Our primary endpoints were median Overall Survival
(mOS) and percentage 1 year Overall Survival (1yrOS).
Secondary endpoints included Objective Response Rate
(ORR), Disease Control Rate (DCR) and median Progression Free Survival (mPFS).
Due to wide variation in study design and reported outcomes, key efficacy endpoints from each individual trial
were summarized. Forest plots were constructed to depict and compare PFS and OS, along with 95% Confidence
Intervals (95% CI) for each trial where relevant data was
available. Pooled data was used to calculate compound
ORR and DCR using a random distribution model.

Results
The identification and screening process as per PRIM-

Additional records identiﬁed
through other sources
(n = 2)

Eligibility

Screening

Records after duplicates removed
(n = 37)

Records screened
(n = 37)

Records excluded
(n = 28)

Full-text articles assessed
for eligibility
(n = 9)

Full-text articles excluded,
with reasons
(n = 0)

Included

Studies included in
qualitative synthesis
(n = 9)

Studies included in
quantitative synthesis
(meta-analysis)
(n = 9)

Figure 1: Study Identification, Screening and Inclusion process (PRISMA flow chart).
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SA guidelines is depicted in Figure 1. Nine articles were
included in this study; including Phase II clinical trials (n
= 2), Expanded Access Programs (EAP) (n = 4) and retrospective studies (n = 3) [14-22]. The key features of each
trial are summarized in Table 1.

in addition to fatigue and fever. Grade 3 or 4 irAEs occurred in 10-33% of cases. IrAE’s were generally reversible when managed as per protocol-specific guidelines.
No new safety signals were seen compared to original
ipilimumab phase 3 studies.

The reported median patient age ranged from 42-67
years. Ipilimumab was prescribed at either a high induction dose (10 mg/kg) or standard dose (3 mg/kg). Reported
mOS ranged from 5.2-28 months, with an overall median
of 9.3 months (mean of 9.1 months) (Figure 2). Progression free survival data was limited and ranged from 2.83.6 (Figure 3). Median PFS could not be calculated for the
reported studies as relevant data was not published or not
provided. The 1yr OS ranged between 4.5-65% (Figure 4).
Calculated compound ORR was 3.4% and compound DCR
was 36%.

Discussion

Eight studies included a toxicity analysis, with immune related adverse effects (irAEs) graded according
to common toxicity criteria. Common irAEs included
rash, itch, diarrhea/colitis, hepatitis, and hypophysitis,

Uveal Melanoma is a rare and highly aggressive tuPFS (95% CI)
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Figure 3: Forest plot of progression free survival from included
trials.
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Figure 2: Forest plot of median Overall Survival (OS) from
included trials.
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Figure 4: Survival % at 1 and 2 years for reported trials.

Table 1: Summary of trials included in meta-analysis.
Study

Design N

Zimmer [15]

Phase II 53

Ipi dose Pre-treated ORR%
(mg/kg)
3
Mixed
0

DCR% mPFS

mOS

1yr OS%

2yr OS%

47

2.8

6.8

22

7

(3.7-8.1)
NR

(12-35)
48.4

(1-18)
24.6

Rodriguez [16] Phase II 32

10

Rx Naive

6.4

45.1

(2.5-2.9)
NR

Deo [14]
Maio [17]

Retro
EAP

24
82

3
3

Pre-Rx
Pre-Rx

(0.79-21.4)
4
5

21
34

2.8
3.6

9.7
6

(33.6-69.6) (12.6-47.8)
45.6
11.4
31
NR

Khattak [18]

EAP

5

3

Pre-Rx

0

40

(2.8-4.4)
NR

(4.3-7.7)
10.3

40

NR

Luke [19]

Retro

39

3/10

Mixed

2.6

46.1

NR

(2.4-20.6)
9.6

NR

NR

4.5

NR

Kelderman [20] EAP

22

3

Pre-Rx

4.5

9

2.9

(6.3-13.4)
5.2

Danielli [21]

13

10

Pre-Rx

0

23

(2.3-5.3)
NR

(4.9-9.6)
9

NR

NR

NR

(0.5-43)
28m

65

NR

Moser [22]

EAP
NR

23

NR

Pre-Rx

NR

NR

(12-38)
NR: Not Reported; ORR: Objective Response Rate; PFS: Progression Free Survival; OS: Overall Survival; DCR: Disease Control Rate.
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mour, with limited treatment options. Data on the activity of ipilimumab amongst patients with advanced UM is
scarce. This pooled analysis contributes to the existing
literature by summarizing the key efficacy endpoints in
published trials and abstracts.
In terms of our activity endpoints, the reported efficacy of ipilimumab in UM is modest at best. However,
median overall survival of 9.3 months amongst patients
with UM treated with ipilimumab (range 5.2-28 months)
is similar to the published mOS of cutaneous melanoma
patients treated with ipilimumab [11,12]. The calculated
compound ORR was disappointingly low (3.4%), but the
compound DCR was potentially more promising (36%).
Most of the published data assessing the efficacy of
ipilimumab focuses on response rate and median overall survival as primary endpoints. At least one abstract
suggests that survival at 1-2 years is more relevant to
assess the efficacy of ipilimumab, given the highly aggressive nature of the disease [14]. The long term benefit with ipilimumab in metastatic melanoma is noted by
a consistent absolute increase of approximately 10% of
patients alive in the ipilimumab-containing arms compared to the control therapy in the two pivotal clinical
trials [11,12]. The late plateau or tail represents the
long term responders. Therefore survival at certain time
points like 1 and 2 yr OS% are more meaningful in the
context of advanced UM. The 1 year OS% with ipilimumab in advanced UM in our analysis ranged between
4.5-65%.
Importantly, the toxicity profile described by these
studies was comparable to the description and frequency of irAEs among patients with cutaneous melanoma
treated with equivalent doses of ipilimumab. Whilst
serious adverse events (grade 3/4) were common, they
were easily managed and usually reversible when treated as per study protocol with steroids.
More recently, there have been studies with anti-programmed cell death protein 1 antibody (anti-PD1)
monotherapy and targeted therapy with MEK inhibitors
that have demonstrated some activity [23-25]. Although
at least one small series has observed activity with pembrolizumab, more extensive experience suggests that
responses and clinical benefit are much more limited
than with advanced cutaneous melanoma [23,24]. The
role of the newer agents in the treatment landscape for
advanced UM needs to be determined and clinically justified bearing in mind the toxicity seen especially with
targeted therapy [25].
One major limitation to this analysis is the heterogeneity of the studies selected. There was a lack of consistency between studies and the wide variation in study
design, inclusion criteria and response assessment criteria is reflected in the wide variation in reported outcomes. There was limited consistency in choice of primary and secondary efficacy outcomes, with confidence
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intervals not reported in several studies. We were unable to retrieve more complete data by contacting the
primary investigators despite our efforts to do so. Sample size in all these studies is relatively small and most
are retrospective. It is possible that the inclusion of results from EAPs predisposes investigators to a positive
publication bias.

Conclusion
Despite the limitations of the published data, we
think there is reasonable evidence to suggest that ipilimumab has modest clinical activity and manageable
toxicity when used in the treatment of advanced UM
in the absence of any other suitable systemic therapy
options. Future studies should explore newer immunotherapies and targeted therapies either as monotherapy or in combination.
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